SNAP25是早期阿尔茨海默病和帕金森病的潜在目标
Qian Wang1, Sijue Tao2, Lei Xing3
1Department of Radiology, Xuzhou Central Hospital, Xuzhou, 221004, Jiangsu, China.
European journal of medical research
|December 5, 2023
概括
嗅觉上皮层中的突触体相关蛋白25 (SNAP25) 可能是早期阿尔茨海默病 (AD) 和帕金森病 (PD) 检测和干预的关键生物标志物,为它们的共同机制提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 和帕金森病 (PD) 具有类似嗅觉功能障碍的早期症状,但它们的并发症机制尚不清楚.
- 了解共享的途径对于诊断和治疗这些不可逆转的神经退行性疾病至关重要.
研究的目的:
- 阐明AD和PD共患病的基础分子机制.
- 确定早期检测的潜在生物标志物和两种疾病的治疗点.
主要方法:
- 对基因表达特征 (GSE5281,GSE8397) 的生物信息分析,以确定重叠的差异表达基因 (DEG).
- 在小鼠模型 (APP/PS-1,A53T) 和嗅觉组织中使用Cytoscape和RT-qPCR识别和验证枢纽基因.
- 分子对接以选潜在的药物化合物,针对已识别的枢纽基因.
主要成果:
- 在AD和PD之间确定了174个重叠的DEG,其中与突触功能相关的途径是突出的.
- 鉴定并验证了五个枢纽基因;在嗅觉上皮层/球泡中,突触体相关蛋白25 (SNAP25) mRNA水平显著降低.
- 嗅觉组织中的SNAP25表达与海马体 (AD模型) 和黑色物质 (PD模型) 的变化密切相关.
结论:
- 嗅觉上皮质中的SNAP25是AD和PD的潜在共同因子和早期生物标志物.
- 针对SNAP25提供了一个有前途的战略,用于早期诊断和治疗干预神经退行性疾病.
- 这项研究为理解AD-PD并发症提供了理论基础.
相关概念视频
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


